AAV8 Gene Therapy DTX401 Reduces Cornstarch Dependence by 41% in Patients with Glycogen Storage Disease Type Ia
Background
Glycogen storage disease type Ia (GSDIa) is an autosomal recessive disorder caused by pathogenic variants in both alleles of the G6PC gene, leading to a deficiency of glucose-6-phosphatase. This enzyme is essential for the final step of converting stored glycogen in the liver into glucose or producing glucose through gluconeogenesis and releasing it into the bloodstream. Prolonged fasting can lead to severe hypoglycemia and lactic acidosis, and long-term risks include hypertriglyceridemia and complications affecting the liver and kidneys.
The current standard of care is a dietary regimen involving the frequent consumption of uncooked cornstarch to continuously supply glucose. While life-saving, this approach imposes restrictions on daily routines, sleep, and academic activities due to the need for nighttime administration and careful meal management. Improper dosing can result in hypoglycemia or excessive carbohydrate intake. In the absence of an approved therapy to restore the deficient enzyme, a strategy involving delivering a functional G6PC gene to hepatocytes to revive endogenous glucose production has emerged as a promising alternative.
Key Findings
The phase 3 DTX401-CL301 trial is a double-blind, randomized, placebo-controlled study in patients aged 8 years and older with GSDIa. DTX401 is an investigational adeno-associated virus 8 (AAV8) vector carrying the human G6PC gene, targeting the liver for gene delivery. Of the 46 randomized participants, 21 received DTX401 and 25 received placebo. The first 48 weeks constituted the primary efficacy analysis period, followed by an additional 48 weeks of blinded crossover observation.
According to the abstract, the least squares mean reduction in daily cornstarch intake at Week 48 was 41% in the DTX401 group versus 10% in the placebo group, with standard errors of 4.6 and 4.1, respectively. The intergroup difference was statistically significant (p < 0.0001). The improvement was not merely numerical. Among the 33 participants who expressed their desired reduction in baseline interviews, the mean desired reduction was 45% and the median was 41%, closely aligning with the actual treatment effect.
At Week 96, participants who switched from placebo to DTX401 showed faster and greater reductions in cornstarch intake compared to the initial DTX401 group. The treatment effect in the first DTX401 group also expanded over 96 weeks. Safety was generally acceptable, although expected transaminase elevations, common in AAV liver-targeted therapies, were observed and managed with prophylactic corticosteroids.
Implications and Outlook
These results suggest the potential to shift the treatment goal for GSDIa from repeated carbohydrate supplementation to address hypoglycemia, toward functional restoration of the deficient gene. The alignment between the patients' desired reduction and the 48-week efficacy further supports the notion that cornstarch intake is not just a statistical measure but a true reflection of treatment burden. The demonstration of efficacy in a placebo-controlled phase 3 trial also elevates the evidence level beyond previous small open-label trials.
However, a 41% reduction in cornstarch intake does not mean the dietary regimen can be discontinued or the disease cured. The trial involved only 46 participants in a rare disease, and the response across age groups and the long-term sustainability of gene expression remain to be confirmed. Considerations such as transaminase elevations, steroid use burden, and the potential for AAV immune responses and re-administration are also important before clinical adoption. Long-term follow-up beyond 96 weeks will be necessary to assess blood glucose stability, reductions in liver and kidney complications, and improvements in quality of life to fully understand the treatment's overall value.
Glycogen storage disease type Ia (GSDIa) is a rare, life-threatening inherited carbohydrate metabolism disorder caused by biallelic pathogenic G6PC gene variants resulting in deficiency of glucose-6-phosphatase. DTX401 is an investigational AAV8 vector containing the human G6PC gene. DTX401-CL301 is a pivotal, phase 3, double-blind, randomized, placebo-controlled trial of DTX401 in patients ≥ 8 years with GSDIa. The primary endpoint was percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 versus placebo group. Participants were randomly assigned (1:1) to blinded DTX401 or placebo. After the 48-week Primary Efficacy Analysis Period (PEAP), participants crossed over in a blinded manner for an additional 48-week blinded Crossover Period. Following randomization: 21 participants received DTX401; 25 received placebo. At Week 48, DTX401 treatment resulted in a statistically significant least squares (LS) mean (SE) daily cornstarch intake reduction of 41% (4.6) versus 10% (4.1) for Placebo (p < 0.0001). Clinical meaningfulness was evidenced by a mean desired percent reduction in daily cornstarch intake among those reporting in Baseline interviews (n = 33) of 45% (median = 41%). Greater and faster reductions in cornstarch were observed at Week 96 for the Crossover DTX401 group compared with the DTX401 group in the PEAP. The DTX401 safety profile was acceptable, and expected hepatic reactions consisting of transaminase elevations were managed with prophylactic corticosteroids. Treatment with DTX401 resulted in both a statistically significant and clinically meaningful reduction in cornstarch intake in the 48-week PEAP versus placebo, with greater cornstarch reductions in both groups at Week 96.
If introduced into clinical practice, DTX401 has the potential to reduce the management burden for patients who must measure and consume uncooked cornstarch at fixed intervals and remain vigilant about nocturnal hypoglycemia. For example, a reduction in the number of daily doses or the amount per dose could allow for more flexible planning of sleep, school, work, and travel. Healthcare providers should implement continuous glucose monitoring and gradual dietary adjustments to reduce cornstarch intake, while closely monitoring liver enzymes and steroid-related side effects during the initial treatment phase. From an industry perspective, the long-term follow-up framework for small rare disease gene therapies, AAV8 antibody screening, site certification, and cost and reimbursement models will likely determine the actual accessibility of the treatment.